Expert opinion: the therapeutic challenges faced by statin intolerance (Q38851603)

7 September 2017

1 reference

title

Expert opinion: the therapeutic challenges faced by statin intolerance (English)

1 reference

7 September 2017

3

Maciej Banach

1 reference

7 September 2017

Jaideep Patel

1

0 references

author name string

Seth S Martin

series ordinal

2

1 reference

PubMed ID

27254275

7 September 2017

language of work or name

English

0 references

publication date

2 June 2016

1 reference

Expert Opinion on Pharmacotherapy

7 September 2017

1 reference

7 September 2017

17

1 reference

7 September 2017

1497-1507

1 reference

7 September 2017

11

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

7 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Non-cardiovascular effects associated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

An assessment by the Statin Muscle Safety Task Force: 2014 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Statin Intolerance: the Clinician's Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Insights Into Statin Intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Management of statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effect of statins on skeletal muscle function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Outcomes in 45 patients with statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Statin rebound or withdrawal syndrome: does it exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Phenotype standardization for statin-induced myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Discontinuation of statins in routine care settings: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

N-of-1 (single-patient) trials for statin-related myalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Clinical Pharmacokinetics of Atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Decreasing LDL cholesterol and medication cost with every-other-day statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Efficacy of alternate-day dosing versus daily dosing of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Ezetimibe and statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Worsening myopathy associated with ezetimibe in a patient with McArdle disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Monotherapy with ezetimibe causing myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Elevation of CKP induced by ezetimibe in monotherapy: report on two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Striated muscle safety of ezetimibe/simvastatin (Vytorin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effectiveness of thrice weekly ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effect of coenzyme q10 on myopathic symptoms in patients treated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Pharmacogenomics, lipid disorders, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Genetic and immunologic susceptibility to statin-related myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Balancing the dilution and oddity effects: decisions depend on body size

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Randomized Polypill crossover trial in people aged 50 and over

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Patient, physician, and payment predictors of statin adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Predictors of nonadherence to statins: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Adherence to cardiovascular disease medications: does patient-provider race/ethnicity and language concordance matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

An assessment by the Statin Liver Safety Task Force: 2014 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

GATM gene variants and statin myopathy risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1197202

10.1080/14656566.2016.1197202

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27254275